Fanlin Li

Title: The Innovations of Fanlin Li

Introduction

Fanlin Li is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of biotechnology, particularly in the development of chimeric antigen receptors (CARs). With a total of 2 patents, his work focuses on enhancing the capabilities of CAR-T cells for improved cancer treatment.

Latest Patents

Li's latest patents include innovative designs for chimeric antigen receptors. The first patent, titled "Chimeric antigen receptor and use thereof," describes a CAR that incorporates a targeting moiety, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain. This CAR specifically binds to variable regions Vα and Vβ of a T cell receptor (TCR) and/or fragments thereof. The second patent, "Chimeric antigen receptor comprising co-stimulatory receptor and application thereof," presents a CAR that includes a co-stimulatory receptor. This CAR has a structure of scFv(X)-(Y)CD3zeta-2A-(Z), where X represents a tumor-targeting antibody or a ligand capable of binding to a tumor. The invention also details CAR-T cells constructed using a recombinant expression vector of the described chimeric antigen receptor, significantly enhancing their tumor-killing and amplification abilities.

Career Highlights

Fanlin Li has worked with notable organizations such as Shanghai Longyao Biotechnology Inc., Ltd. and Shanghai Jiaotong University. His experience in these institutions has allowed him to advance his research and contribute to the field of biotechnology.

Collaborations

Li has collaborated with several professionals in his field, including Xuanming Yang and Yangxin Fu. These collaborations have further enriched his research and development efforts.

Conclusion

Fanlin Li's innovative work in the development of chimeric antigen receptors showcases his commitment to advancing cancer treatment technologies. His contributions are paving the way for more effective therapies in the fight against cancer.